These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 25915038)

  • 1. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
    Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
    PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro.
    Kunnimalaiyaan S; Schwartz VK; Jackson IA; Clark Gamblin T; Kunnimalaiyaan M
    BMC Cancer; 2018 May; 18(1):560. PubMed ID: 29751783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-Benzyl-indole-3-carbinol is a highly potent new small molecule inhibitor of Wnt/β-catenin signaling in melanoma cells that coordinately inhibits cell proliferation and disrupts expression of microphthalmia-associated transcription factor isoform-M.
    Kundu A; Khouri MG; Aryana S; Firestone GL
    Carcinogenesis; 2017 Dec; 38(12):1207-1217. PubMed ID: 29028954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
    Chiu CS; Tsai CH; Hsieh MS; Tsai SC; Jan YJ; Lin WY; Lai DW; Wu SM; Hsing HY; Arbiser JL; Sheu ML
    Cancer Lett; 2019 Feb; 442():113-125. PubMed ID: 30391358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo anti-tumor activity of CoQ0 against melanoma cells: inhibition of metastasis and induction of cell-cycle arrest and apoptosis through modulation of Wnt/β-catenin signaling pathways.
    Hseu YC; Thiyagarajan V; Tsou HT; Lin KY; Chen HJ; Lin CM; Liao JW; Yang HL
    Oncotarget; 2016 Apr; 7(16):22409-26. PubMed ID: 26968952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nuclear beta-catenin localization is not sufficient for canonical Wnt signaling activation in human meianoma cell lines].
    Kulikova KV; Posviatenko AV; Gnuchev NV; Georgiev GP; Kibardin AV; Larin SS
    Mol Biol (Mosk); 2011; 45(5):884-91. PubMed ID: 22393786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.
    Gray JE; Infante JR; Brail LH; Simon GR; Cooksey JF; Jones SF; Farrington DL; Yeo A; Jackson KA; Chow KH; Zamek-Gliszczynski MJ; Burris HA
    Invest New Drugs; 2015 Dec; 33(6):1187-96. PubMed ID: 26403509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
    Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational small-molecule drug selectively suppresses constitutive CYP2B6 activity at the gene transcription level: physiologically based pharmacokinetic model assessment of clinical drug interaction risk.
    Zamek-Gliszczynski MJ; Mohutsky MA; Rehmel JL; Ke AB
    Drug Metab Dispos; 2014 Jun; 42(6):1008-15. PubMed ID: 24658455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators.
    Mazur M; Bujak A; Matloka M; Janowska S; Gunerka P; Bojarski L; Stanczak A; Klejman A; Bednarek A; Lamparska-Przybysz M; Wieczorek M
    Anal Biochem; 2015 Apr; 475():56-67. PubMed ID: 25659657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling.
    Liu Y; Liu YZ; Zhang RX; Wang X; Meng ZJ; Huang J; Wu K; Luo JY; Zuo GW; Chen L; Yin LJ; Deng ZL; He BC
    Int J Oncol; 2014 Aug; 45(2):795-803. PubMed ID: 24859848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
    Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
    Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.
    Capasso A; Bagby SM; Dailey KL; Currimjee N; Yacob BW; Ionkina A; Frank JG; Kim DJ; George C; Lee YB; Benaim E; Gittleman B; Hartman SJ; Tan AC; Kim J; Pitts TM; Eckhardt SG; Tentler JJ; Diamond JR
    Mol Cancer Ther; 2019 Nov; 18(11):1916-1925. PubMed ID: 31488700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
    Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
    Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.
    Etnyre D; Stone AL; Fong JT; Jacobs RJ; Uppada SB; Botting GM; Rajanna S; Moravec DN; Shambannagari MR; Crees Z; Girard J; Bertram C; Puri N
    Cancer Biol Ther; 2014 Sep; 15(9):1129-41. PubMed ID: 24914950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.